Ireland's Health Service Executive has approved Novartis' gene therapy Zolgensma for use under reimbursement to treat children with spinal muscular atrophy (SMA), reported The Irish Times.
The therapy has a one-off treatment cost of $2.1 million in the US.
Ireland reached a price agreement as a member of the BeNeLuxA Initiative, a partnership approach to pharmaceutical policy with Belgium, the Netherlands, Luxembourg and Austria.
The scheme aims to secure sustainable access to high quality and affordable medicines for participating countries.
Considerable engagement and negotiation with Novartis has allowed Belgium, Ireland and the Netherlands to jointly reach an agreement on the price of a drug for the first time, according to the Irish department of health.
Zolgensma was granted conditional marketing authorisation in the EU in May 2020.
To read more NewsPoints articles, click here.